CAJ | 학술논문

随着人们生活水平的不断提高,生活习惯的改变,糖尿病目前已经成为危害人类健康的主要疾病之一。据国际糖尿病联盟(IDF)统计,糖尿病患者人数呈逐年增长趋势,并趋于年轻化。 DPP-Ⅳ抑制剂(二肽基肽酶郁抑剂,dipeptidyl peptidase-4 inhibitors)作为一种新型的口服降糖药,已经开始应用于临床,无论是单独还是联合用药,都表现出可靠的有效性和安全性,它们能够有效降低空腹血糖、HbA1c水平,并具有不影响胃排空、较少发生低血糖和体重增加等优点,为糖尿病患者提供了新的治疗途径。主要介绍了目前已上市的五种DPP-Ⅳ抑制剂及其药动学特点,着重介绍了DPP-Ⅳ抑制剂作为一类新型降糖药物,单独治疗及联合治疗与其他类别降糖药相比降糖效果如何。
수착인문생활수평적불단제고,생활습관적개변,당뇨병목전이경성위위해인류건강적주요질병지일。거국제당뇨병련맹(IDF)통계,당뇨병환자인수정축년증장추세,병추우년경화。 DPP-Ⅳ억제제(이태기태매욱억제,dipeptidyl peptidase-4 inhibitors)작위일충신형적구복강당약,이경개시응용우림상,무론시단독환시연합용약,도표현출가고적유효성화안전성,타문능구유효강저공복혈당、HbA1c수평,병구유불영향위배공、교소발생저혈당화체중증가등우점,위당뇨병환자제공료신적치료도경。주요개소료목전이상시적오충DPP-Ⅳ억제제급기약동학특점,착중개소료DPP-Ⅳ억제제작위일류신형강당약물,단독치료급연합치료여기타유별강당약상비강당효과여하。
With the continuous improvement of people's living standards and changes in lifestyle, diabetes has become one of the major diseases that threaten human health. According to the International Diabetes Federation (IDF) statistics, the number of patients with diabetes increases year by year, and the age tends to be younger. As novel oral hypoglycemic agents, Dipeptidyl peptidase-4 (DPP-Ⅳ) inhibitors have been widely used in clinical and demonstrated effective and safe, either alone or in combination with other hypoglycemics. They are able to reduce fasting blood glucose and HbA1c levels effectively while do not affect gastric emptying and with less probability of hypoglycemia and weight gain, which provide for diabetics a new therapeutic approach. This paper describes the current five DPP-Ⅳ inhibitors and their pharmacokinetic characteristics listed, highlighting the effect of DPP-Ⅳ inhibitors which as a new class of antidiabetic drugs comparing between other classes of antidiabetic drug with monotherapy and combination therapy.